QBL Engagement of Israeli Research Organisation fo
Post# of 288
(Total Views: 376)
Posted On: 03/28/2018 7:32:50 PM
QBL Engagement of Israeli Research Organisation for the Development of Medical Cannabis Products
Sydney, Australia - Queensland Bauxite Limited is pleased to announce further to the significant progress its subsidiary Medical Cannabis Limited (MCL) has been making in its business and product development, EndoCRO Ltd an iCAN:Israel-Cannabis company, has been selected as a research and product development arm on contract basis for development of pharmaceutical GMP grade Medical Cannabis products ... with the goal of achieving full approval of products for sale as recognised normative prescription medicinal products in Australia and globally.
EndoCRO, utilising its unique knowledge and expertise in latest available research and technologies, is developing an advanced cannabis formulation utilising pharmaceutical grade drug delivery, expected to be a break-through product ... have a significant edge over currently available medical Cannabis products which generally are NOT PRODUCED TO accepted GMP medical and pharmaceutical grades and standards and generally cannot be accurately dosed, which has been a significant challenge to get these products formally approved by first world government authorities as an established medication. .
Pnina Feldman, Executive Chairperson of QBL said "Israel has lead the world in Medical Cannabis research with an active medical program serving over 30,000 patients. Tapping into their existing advanced medical cannabis ecosystem should significantly expedite the time to get effective scientifically proven and approved medical products to the Australasian market approved by Australian Government under existing legislation ... a massive milestone for the medical Cannabis industry in Australia and globally.
The Cannabis plant has currently a few thousand known different strains, with largely anecdotal evidence as to which strains are good for treating different illnesses and within those strains over 160 different cannabinoids and combinations within those strains it is uncertain which combination is able to achieve the desired result, leaving dosing and prescribing an accurate medication a significant challenge ...". Saul Kaye, CEO of iCAN:Israel-Cannabis said "Contract and clinical research organisations have provided traditional pharmaceutical and wellness companies with specialist knowledge for years, we established one that is now uniquely focused on developing products for the Medical Cannabis market".
Sydney, Australia - Queensland Bauxite Limited is pleased to announce further to the significant progress its subsidiary Medical Cannabis Limited (MCL) has been making in its business and product development, EndoCRO Ltd an iCAN:Israel-Cannabis company, has been selected as a research and product development arm on contract basis for development of pharmaceutical GMP grade Medical Cannabis products ... with the goal of achieving full approval of products for sale as recognised normative prescription medicinal products in Australia and globally.
EndoCRO, utilising its unique knowledge and expertise in latest available research and technologies, is developing an advanced cannabis formulation utilising pharmaceutical grade drug delivery, expected to be a break-through product ... have a significant edge over currently available medical Cannabis products which generally are NOT PRODUCED TO accepted GMP medical and pharmaceutical grades and standards and generally cannot be accurately dosed, which has been a significant challenge to get these products formally approved by first world government authorities as an established medication. .
Pnina Feldman, Executive Chairperson of QBL said "Israel has lead the world in Medical Cannabis research with an active medical program serving over 30,000 patients. Tapping into their existing advanced medical cannabis ecosystem should significantly expedite the time to get effective scientifically proven and approved medical products to the Australasian market approved by Australian Government under existing legislation ... a massive milestone for the medical Cannabis industry in Australia and globally.
The Cannabis plant has currently a few thousand known different strains, with largely anecdotal evidence as to which strains are good for treating different illnesses and within those strains over 160 different cannabinoids and combinations within those strains it is uncertain which combination is able to achieve the desired result, leaving dosing and prescribing an accurate medication a significant challenge ...". Saul Kaye, CEO of iCAN:Israel-Cannabis said "Contract and clinical research organisations have provided traditional pharmaceutical and wellness companies with specialist knowledge for years, we established one that is now uniquely focused on developing products for the Medical Cannabis market".
(0)
(0)
Robert
Scroll down for more posts ▼